Curaleaf (OTCMKTS:CURLF) Stock Price Down 6.8% – Here’s What Happened
by Jessica Moore · The Cerbat GemShares of Curaleaf Holdings, Inc. (OTCMKTS:CURLF – Get Free Report) were down 6.8% during mid-day trading on Tuesday . The stock traded as low as $2.22 and last traded at $2.2550. Approximately 601,954 shares changed hands during mid-day trading, a decline of 32% from the average daily volume of 884,387 shares. The stock had previously closed at $2.42.
Analyst Ratings Changes
Several equities research analysts recently issued reports on CURLF shares. Zacks Research upgraded Curaleaf from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Alliance Global Partners reiterated a “buy” rating on shares of Curaleaf in a report on Monday, December 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy”.
View Our Latest Stock Report on Curaleaf
Curaleaf Trading Up 1.2%
The company has a current ratio of 1.52, a quick ratio of 0.76 and a debt-to-equity ratio of 1.14. The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of -8.13 and a beta of 0.77. The company has a fifty day moving average of $2.31 and a 200-day moving average of $2.59.
Curaleaf (OTCMKTS:CURLF – Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.03. The company had revenue of $333.07 million for the quarter, compared to analysts’ expectations of $328.70 million. Curaleaf had a negative return on equity of 23.17% and a negative net margin of 18.08%. As a group, equities research analysts anticipate that Curaleaf Holdings, Inc. will post -0.25 earnings per share for the current fiscal year.
About Curaleaf
Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.
Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.